Parabilis Medicines Inc (PBLS)

Aug 19, 2026

Parabilis Medicines Price Insights - YCharts

Aug 19, 2026

Aug 19, 2026

Parabilis Medicines, Inc. Common Stock (NASDAQ: PBLS) Stock Price, News & Analysis - Kalkine

Aug 19, 2026

Aug 19, 2026

Top Parabilis Medicines (PBLS) Competitors 2026 - MarketBeat

Aug 19, 2026

Aug 18, 2026

Parabilis Medicines (NASDAQ:PBLS) Stock Price Up 5.9%Here's What Happened - MarketBeat

Aug 18, 2026

Aug 18, 2026

Alphabet Inc. Makes New $134.65 Million Investment in Parabilis Medicines, Inc. $PBLS - MarketBeat

Aug 18, 2026

Aug 17, 2026

symbol__ Stock Quote Price and Forecast - CNN

Aug 17, 2026

Aug 17, 2026

Biotech’s reverse merger renaissance poised to continue - Endpoints News

Aug 17, 2026

Aug 17, 2026

Parabilis Medicines (NASDAQ:PBLS) Sets New 1-Year HighWhat's Next? - MarketBeat

Aug 17, 2026

Aug 17, 2026

Focus Partners Advisor Solutions LLC Invests $1.35 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Aug 17, 2026

Aug 14, 2026

Parabilis Medicines(PBLS) Stock Options Chain | Quotes & News - Moomoo

Aug 14, 2026

Aug 14, 2026

Parabilis Medicines Inc. (PBLS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Aug 14, 2026

Aug 14, 2026

Parabilis Medicines (PBLS): ARCH Venture group discloses 6.4M-share, 5.3% ownership - Stock Titan

Aug 14, 2026

Aug 14, 2026

BofA Securities Maintains Parabilis Medicines(PBLS.US) With Buy Rating - Moomoo

Aug 14, 2026

Aug 14, 2026

Parabilis Medicines: A Rare-Tumor Validation Ladder For An Undruggable Platform (NASDAQ:PBLS) - Seeking Alpha

Aug 14, 2026

Aug 14, 2026

PBLS SWOT Analysis: Financial Resilience Amidst Clinical Challen - GuruFocus

Aug 14, 2026

Aug 13, 2026

Parabilis Medicines (PBLS) Earnings Date and Reports 2026 - MarketBeat

Aug 13, 2026

Aug 13, 2026

Parabilis Medicines: Q2 Earnings Snapshot - AOL.com

Aug 13, 2026

Aug 13, 2026

Parabilis Medicines (PBLS) boosts cash above $1.1B after IPO and Regeneron deal - Stock Titan

Aug 13, 2026

Aug 13, 2026

Form 8K Parabilis Medicines For: 13 August By Investing.com - Investing.com Nigeria

Aug 13, 2026

Aug 13, 2026

PBLS: Lead asset zolucatetide shows strong efficacy and safety, driving a robust pipeline and growth - TradingView

Aug 13, 2026

Aug 13, 2026

Parabilis Medicines Q2 Loss Narrows; Shares Rise Pre-Bell - marketscreener.com

Aug 13, 2026

Aug 13, 2026

Earnings Flash (PBLS) Parabilis Medicines Posts Q2 Net Loss $2.32 a Share - marketscreener.com

Aug 13, 2026

Aug 13, 2026

Parabilis Medicines Reports Second Quarter 2026 Financial Results And Provides Business Updates - TradingView

Aug 13, 2026

Aug 13, 2026

Earnings Flash (PBLS) Parabilis Medicines, Inc. Reports Q2 Revenue $148,000 - marketscreener.com

Aug 13, 2026

Aug 13, 2026

Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times

Aug 13, 2026

Aug 13, 2026

Parabilis Medicines Advances Zolucatetide Toward Phase 3 in Desmoid Tumors, Announces Regeneron Collaboration and $1.1 Billion Cash Position - Quiver Quantitative

Aug 13, 2026

Aug 10, 2026

Parabilis Medicines (NASDAQ:PBLS) Reaches New 1-Year HighWhat's Next? - MarketBeat

Aug 10, 2026

Aug 08, 2026

Parabilis Medicines Ord Shs (PBLS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Aug 08, 2026

Aug 07, 2026

Parabilis Medicines, Inc.Common Stock (Nasdaq:PBLS) Stock Quote - The Chronicle-Journal

Aug 07, 2026

Aug 07, 2026

Alphabet Reports Share Stake In SpaceX, Fervo Energy And Parabilis Medicines - TradingView

Aug 07, 2026

Aug 07, 2026

Parabilis Medicines (PBLS) Institutional Ownership 2026 - MarketBeat

Aug 07, 2026

Aug 06, 2026

FMR LLC reports 10.3M-share position in Parabilis Medicines Inc (PBLS) - Stock Titan

Aug 06, 2026

Aug 01, 2026

Parabilis Medicines, Inc. (NASDAQ:PBLS) Given Average Recommendation of "Buy" by Analysts - marketbeat.com

Aug 01, 2026

Jul 28, 2026

PBLS|Parabilis Medicines Ord Shs|Price:31.820|Chg%:+0.540 - TradingKey

Jul 28, 2026

Jul 27, 2026

Alexis Borisy: Biotech Is Winning the Science and Losing the Story - finance.biggo.com

Jul 27, 2026

Jul 25, 2026

Parabilis Medicines, Inc. Revenue Breakdown – NASDAQ:PBLS - TradingView

Jul 25, 2026

Jul 23, 2026

Scribe secures $129M in a rare gene editing IPO - BioPharma Dive

Jul 23, 2026

Jul 23, 2026

Parabilis Medicines(PBLS.US) 10% Shareholder Buys US$6.92 Million in Common Stock - Moomoo

Jul 23, 2026

Jul 23, 2026

Form 4 Parabilis Medicines For: 22 July - Investing.com India

Jul 23, 2026

Jul 23, 2026

Form 4 Parabilis Medicines For: 22 July By Investing.com - Investing.com South Africa

Jul 23, 2026

Jul 22, 2026

Parabilis Medicines, Inc. (PBLS) Revenue (TTM) - Zacks Investment Research

Jul 22, 2026

Jul 22, 2026

RA Capital boosts stake in Parabilis Medicines (PBLS) with stock buys - Stock Titan

Jul 22, 2026

Jul 22, 2026

Parabilis Medicines (PBLS) 10K Form and Latest SEC Filings 2026 - MarketBeat

Jul 22, 2026

Jul 21, 2026

Parabilis tops Kailera as biopharma IPOs surge to best H1 since 2021 - BioWorld News

Jul 21, 2026

Jul 19, 2026

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Jul 19, 2026

Jul 18, 2026

LifeSci Capital Initiates Parabilis Medicines(PBLS.US) With Buy Rating, Announces Target Price $42 - Moomoo

Jul 18, 2026

Jul 17, 2026

With record listing prices, what the mid-year IPO market says about the current state of biopharma - The Pharma Letter

Jul 17, 2026

Jul 17, 2026

Primary Markets Group June 2026 U.S. IPO Update - Seeking Alpha

Jul 17, 2026

Jul 14, 2026

Parabilis Medicines, Inc. (NASDAQ:PBLS) Sees Significant Increase in Short Interest - MarketBeat

Jul 14, 2026

Jul 13, 2026

PBLS Price Today: Parabilis Medicines, Inc. Stock Price, Quote & Chart - mexc.co

Jul 13, 2026